COVID-19 vaccination in Switzerland

Last updated

COVID-19 vaccination in Switzerland
DateDecember 22, 2021 (2021-12-22) – present
Location Switzerland
Cause COVID-19 pandemic in Switzerland

COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

By 14 November 2023, 17,015,053 doses of COVID-19 vaccine have been administered. [1]

Background

Lonza Group in Visp where the Moderna COVID-19 vaccine is produced. Site Lonza de Viege, vu depuis la gare de Lalden 2.JPG
Lonza Group in Visp where the Moderna COVID-19 vaccine is produced.

On 19 December 2020, the Swiss Agency for Therapeutic Products (Swissmedic) approved the Pfizer–BioNTech COVID-19 vaccine (Comirnaty) for regular use, two months after receiving the application, although it was expected to give a decision later than other European countries, as Swiss laws do not allow emergency approvals. After the application was processed with high priority using all the available resources, the head of Swissmedic stated that the vaccine fully complied with the requirements of safety, efficacy, and quality. This constituted the first authorization by a stringent regulatory authority under a standard procedure for any COVID-19 vaccine. [2] [3] Three days later, 107 000 vaccine shots were received by the army to be dispatched in the cantons. On 23 December, 302 days after the first official case, the first patient, a 90-year-old woman from Central Switzerland, was vaccinated in a retirement home in Lucerne. [4] On that day, the cantons of Lucerne, Zug, Schwyz, Nidwalden and Appenzell Innerrhoden launched the vaccination campaign, [5] marking the beginning of mass vaccination in Switzerland and continental Europe outside Russia. [6] Most cantons followed by 4 January 2021 and all the rest of them by 11 January. By that day, about 0.5% of the population received the Pfizer–BioNTech COVID-19 vaccine. [7]

On 12 January 2021, Swissmedic approved the second COVID-19 vaccine: the mRNA-1273 made by Moderna. [8] [9] The Lonza Group where the vaccine is produced was visited by Federal Councilor Alain Berset the previous day. Up to 800,000 vaccines per day are expected to be produced there. A year after the first COVID-19 outbreak, the number of vaccinated people largely outnumbered the official cases. On 7 March, about 10% of the population received at least one shot of the two approved vaccines (Pfizer and Moderna) and about 3% were fully vaccinated. [10]

A third vaccine, the Oxford/AstraZeneca vaccine (AZD1222), which comprised 5.3 million of the doses ordered by Swiss authorities, was rejected for approval by the Swiss medical authority, SwissMedic, citing insufficient data. [11]

In March 2021, the Swiss Federal Health Ministry reported that approved vaccine deliveries have increased steadily every month. Switzerland received 1.1 million doses of the Moderna and Pfizer vaccines in January and February 2021, and another 1 million vaccine doses in March, exceeding initial expectations. As of 14 November, there have been 6,123,678 people who have taken the first dose of coronavirus vaccine. [12] [13] The country plans to have its 8.6 million residents vaccinated by summer 2021. [14]

In April 2021, there were reports that vaccine administration and production efforts at the Lonza Group plant in Visp have been hampered due to overly stringent immigration rules in Switzerland, reducing the influx of qualified biotech and healthcare workers, particularly with regard to non-EU/EFTA states. The Valais National Council urged the Swiss federal authorities to create exemptions from the current immigration rules for essential biotech industries. [15]

Drive In vaccination in Thun (March 2021) Covid-19-Impfzentrum Thun 01.jpg
Drive In vaccination in Thun (March 2021)

Vaccines on order

VaccineApprovalDeployment
Pfizer–BioNTech Green check.svg December 19, 2020Green check.svg Yes
Moderna Green check.svg January 12, 2021Green check.svg Yes
Janssen Green check.svg March 22, 2021Green check.svg Yes
Novavax Green check.svg April 13, 2022Green check.svg Yes

Related Research Articles

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">Moderna COVID-19 vaccine</span> RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus.

<span class="mw-page-title-main">Operation Warp Speed</span> US program to accelerate COVID-19 vaccine efforts

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.

<span class="mw-page-title-main">Pfizer–BioNTech COVID-19 vaccine</span> Type of vaccine for humans

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in humans to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) that encodes a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial guidance recommended a two-dose regimen, given 21 days apart; this interval was subsequently extended to up to 42 days in the United States, and up to four months in Canada.

<span class="mw-page-title-main">COVID-19 vaccination in the United Kingdom</span> Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom.

<span class="mw-page-title-main">COVID-19 vaccination in Italy</span> Immunization plan against COVID-19 in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

<span class="mw-page-title-main">COVID-19 vaccination in Israel</span> Plan to immunize against COVID-19

Israel's COVID-19 vaccination programme, officially named "Give a Shoulder", began on 19 December 2020, and has been praised for its speed, having given twenty percent of the Israeli population the first dose of the vaccines' two dose regimen in the span of three weeks.

<span class="mw-page-title-main">Deployment of COVID-19 vaccines</span> Distribution and administration of COVID-19 vaccinations

As of 3 January 2024, 13.53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">COVID-19 vaccination in Australia</span> Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Canada</span> COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Indonesia</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

<span class="mw-page-title-main">COVID-19 vaccination in Singapore</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore has a very high vaccination rate, with more than 92% of its total population having completed their vaccination regimen.

COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.

<span class="mw-page-title-main">COVID-19 vaccination in Ukraine</span> Plan to immunize against COVID-19

The COVID-19 vaccination campaign in Ukraine is an ongoing mass immunization campaign for the COVID-19 pandemic in Ukraine.

COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.

References

  1. ↑ "COVID-⁠19 Switzerland | Coronavirus | Dashboard". www.covid19.admin.ch. Retrieved November 7, 2021.
  2. ↑ "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). December 19, 2020. Archived from the original on January 10, 2021. Retrieved December 19, 2020.
  3. ↑ "COVID-19: Switzerland can start vaccinating vulnerable groups already in December" (Press release). Federal Office of Public Health. December 19, 2020. Archived from the original on January 9, 2021. Retrieved December 19, 2020.
  4. ↑ Erni, Salome (December 23, 2020). "90-jährige Luzernerin als erste Person in der Schweiz gegen Corona geimpft". Luzerner Zeitung . Archived from the original on January 25, 2021. Retrieved December 23, 2020.
  5. ↑ Brotschi, Markus (December 23, 2020). "Die Impfung ist da – einige Senioren zögern noch". Der Bund . Archived from the original on April 26, 2021. Retrieved December 24, 2020.
  6. ↑ Pralong, Julien (December 23, 2020). "La piqûre de l'espoir pratiquée à Lucerne". Heidi.news. Archived from the original on January 10, 2021. Retrieved December 23, 2020. Le média zurichois affirme même qu'il s'agit-là de la première personne vaccinée en Europe. Indépendamment de cette vaine «course», cette injection marque, pour la Suisse et l'ensemble du continent, un tournant peut-être décisif dans la lutte contre une pandémie...[The Zurich media even claims that this is the first person vaccinated in Europe. Regardless of this vain "race", this injection marks, for Switzerland and the whole of the continent, a perhaps decisive turning point in the fight against a pandemic...]
  7. ↑ "Welche Länder wie schnell impfen". srf.ch . January 13, 2020. Archived from the original on January 14, 2021. Retrieved January 14, 2020.
  8. ↑ "Swissmedic erteilt Zulassung für Moderna-Impfstoff in der Schweiz". SRF. January 12, 2020. Archived from the original on January 12, 2021. Retrieved January 12, 2020.
  9. ↑ "Swissmedic grants authorisation for the COVID-19 vaccine from Moderna". Swissmedic (Press release). January 12, 2020. Archived from the original on February 11, 2021. Retrieved January 12, 2020.
  10. ↑ La vaccination progresse en Suisse, mais l'horizon du "tous vaccinés" est encore lointain Archived April 26, 2021, at the Wayback Machine , rts.ch. Retrieved 07-03-2021. ("Près de 20'000 injections ont lieu tous les jours, ce qui a permis à près de 10% de la population de recevoir au moins une dose, et à 3% d'obtenir les deux requises pour que la couverture vaccinale soit complète.")
  11. ↑ "'Insufficient data': Switzerland declines to approve AstraZeneca vaccine". thelocal.ch. AFP/The Local. February 3, 2021. Archived from the original on April 26, 2021. Retrieved February 18, 2021.
  12. ↑ "CORONAVIRUS IN THE WORLD AS OF WEDNESDAY 17 MARCH 2021: LATEST CASE AND DEATH TOLLS IN 24H PER COUNTRY". Sortiraparis. Julie M. March 17, 2021. Archived from the original on November 7, 2021. Retrieved March 17, 2021.
  13. ↑ "Vaccinations, Switzerland and Liechtenstein". COVID-19 Switzerland. Federal Office of Public Health (FOPH). November 14, 2023. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  14. ↑ Miller, John (9 March 2021). "Switzerland expecting 1 million COVID vaccine doses from Moderna, Pfizer in March" Archived April 26, 2021, at the Wayback Machine . msn.com. Retrieved 13 March 2021.
  15. ↑ "How Switzerland's strict immigration rules might have contributed to slow vaccination rollout" Archived April 28, 2021, at the Wayback Machine . theLocal.ch. Retrieved 28. April 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.